REFERENCES
- Pedersen S. B. Biopharmaceutical aspects of tolfenamic acid. Pharmacol. Toxicol. 1994; 75(11)22–32
- Linden B., Parantainen J., Vapaatalo H. Inhibition of prostaglandin biosynthesis by tolfenamic acid in vitro. Scand. J. Rheumatol 1976; 5: 129–132
- Hakkarainen H., Vapaatalo H., Gothoni G., Parantainen J. Tolfenamic acid is as effective as ergotamine during migraine attacks. Lancet 1976; 2: 326–327
- Szejtli J., Pitha J., Szente L. Molecular encapsulation of drug by cyclodextrins and congeners, in. Controlled Drug Delivery. Vol. I (S. D. Bruck, ed.), CDR Press Inc., FL. 1983; 125–148
- Szejtli J. V. F. Smolen, L. BallMolecular entrapment and release properties of drugs by cyclodextrins. Controlled Drug Bioavailability, . John Wiley and Sons Inc, New York 1985; 3: 365–420
- Yoshida A., Arima H., Uekama K., Pitha J. Pharmaceutical evaluation of hydroxyalkyl ethers of β-cyclodextrins. Int. J. Pharm. 1998; 46: 217–222
- Higuchi T., Connors K. A. C. N. ReilleyPhase-solubility techniques. Advances in Analytical Chemistry and Instrumentation, . John Wiley and Sons, New York 1965; 117–212
- Vavia P. R., Adhage N. A. Inclusion complexation of nimesulide with β-cyclodextrins. Drug Dev. Ind. Pharm. 1999; 25(4)543–545
- Mitrevej N., Sinchaipanid V., Juyaprasert V., Warintornuwat L. Effect of grinding of β-cyclodextrin and glibenclamide on tablet properties. Drug Dev. Ind. Pharm. 1996; 22(12)1237–1241
- Banakar U. V. Dissolution of dosage forms. Pharmaceutical Dissolution Testing. Marcel Dekker, Inc., New York 1992; 251–280